Free Trial
Your Portfolio Deserves Better! MarketBeat All Access for Just $149
Upgrade Now
Claim MarketBeat All Access Sale Promotion
NASDAQ:GNTA

Genenta Science 10/10/2025 Earnings Report

Genenta Science logo
$0.59 -0.03 (-4.56%)
Closing price 03:57 PM Eastern
Extended Trading
$0.61 +0.02 (+3.39%)
As of 05:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Genenta Science EPS Results

Actual EPS
-$0.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Genenta Science Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Genenta Science Announcement Details

Quarter
Date
10/10/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Genenta Science Earnings Headlines

GENENTA SCIENCE SPA: Genenta signs Definitive Agreements with Sophia High Tech
April 23, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-04/68281349-genenta-science-spa-genenta-signs-definitive-agreements-with-sophia-high-tech-399.htm
Genenta signs Definitive Agreements with Sophia High Tech
April 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/23/3279719/0/en/genenta-signs-definitive-agreements-with-sophia-high-tech.html
$30 stock to buy before Starlink goes public (WATCH NOW!)
A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker.tc pixel
May 21 at 1:00 AM  |  Paradigm Press (Ad)
Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs
March 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/27/3263607/0/en/genenta-evolving-into-saentra-forge-has-signed-a-binding-offer-with-s%c3%b2phia-high-tech-an-italian-company-manufacturing-critical-parts-for-europe-s-space-and-defense-programs.html
Genenta Science evaluates biotech partnerships as it shifts strategic focus
March 24, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/genenta-science-evaluates-biotech-partnerships-as-it-shifts-strategic-focus/ar-AA1Zi1Dx
Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini
March 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/24/3260971/0/en/genenta-evolving-into-saentra-forge-continues-to-evaluate-strategic-options-for-its-original-biotechnology-platform-derived-from-the-research-of-professor-luigi-naldini.html
See More Genenta Science Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genenta Science? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genenta Science and other key companies, straight to your email.

About Genenta Science

Genenta Science (NASDAQ:GNTA) (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter. Temferon is currently being evaluated in Phase I/II clinical trials for recurrent high-grade glioma and ovarian carcinoma. Early clinical data have demonstrated a favorable safety profile and promising signs of biological activity, supporting the company’s approach to create a durable anticancer effect while limiting systemic toxicity.

Headquartered in Milan, Italy, with a research and development presence in the United States, Genenta Science collaborates with academic institutions and cancer centers across Europe and North America to advance its clinical programs. The company benefits from strategic partnerships that provide access to leading oncology experts, manufacturing capabilities, and patient networks, positioning it to accelerate enrollment in multi-center trials and to expand its pipeline.

Founded in 2016 as a spin-off from leading academic research institutes, Genenta Science is led by a management team with extensive experience in gene therapy, hematology, and oncology drug development. The company has attracted funding from both private investors and non-dilutive sources to support its growth, with the goal of bringing novel HSC-based immunotherapies to patients with hard-to-treat solid tumors.

View Genenta Science Profile
Earnings Tools